| Overview |
| bs-3799R-Cy5 |
| KLK11 Polyclonal Antibody, Cy5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Dog |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human KLK11 |
| 201-282/282 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 11012 |
| Cytoplasm, Secreted |
| Hippostasin; hK11; KLK 11; KLK-11; kallikrein 11; Kallikrein 11 isoform 1 preproprotein; Kallikrein 11 isoform 2 precursor; Kallikrein 11 precursor; kallikrein related peptidase 11; KLK 11; KLK11; Protease serine 20 trypsin like; Protease serine trypsin like; PRSS20; Serine protease 20; TLSP; Trypsin like protease; KLK11_HUMAN. |
| Kallikrein 11 has two alternative splicing isoforms, known as the brain type and prostate type. Elevated serum levels of hK11 have been found in 70% of women with ovarian cancer and in 60% of men with prostate cancer. Analysis of this biomarker in serum may aid in the diagnosis and monitoring of ovarian and prostatic carcinoma. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz